KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

被引：13
|
作者：
Nanda, R.
Specht, J.
Dees, C.
Berger, R.
Gupta, S.
Geva, R.
Pusztai, L.
Pathiraja, K.
Ray, A.
Karantza, V.
Buisseret, L.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ North Carolina Lineberger Comprehens Canc Ct, Chapel Hill, NC USA
[4] Sheba Med Ctr, Tel Hashomer, Israel
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[7] Yale Univ Sch Med, New Haven, CT 06520 USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study
    Nanda, R.
    Specht, J.
    Dees, E. C.
    Berger, R.
    Gupta, S.
    Geva, R.
    Pusztai, L.
    Pathiraja, K.
    Ray, A.
    Karantza, V.
    Buisseret, L.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S38 - S38
  • [2] Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
    Nanda, Rita
    Chow, Laura Q. M.
    Dees, E. Claire
    Berger, Raanan
    Gupta, Shilpa
    Geva, Ravit
    Pusztai, Lajos
    Pathiraja, Kumudu
    Aktan, Gursel
    Cheng, Jonathan D.
    Karantza, Vassiliki
    Buisseret, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) : 2460 - +
  • [3] Long-Lasting Response after Pembrolizumab in a Patient with Metastatic Triple-Negative Breast Cancer
    Peinado, Paloma
    Ramirez, Carmen
    Garcia-Saenz, Jose Angel
    Pascual, Alejandro
    Fuentes-Antras, Jesus
    Vidal, Natalia
    Antonanzas, Monica
    Moreno, Fernando
    BREAST CARE, 2020, 15 (04) : 428 - 432
  • [4] A phase 2 study of pembrolizumab (MK-3475) monotherapy for metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086
    Adams, S.
    Card, D.
    Zhao, J.
    Karantza, V.
    Aktan, G.
    CANCER RESEARCH, 2016, 76
  • [5] A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth
    Kaufman, Peter A.
    Wilks, Sharon
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
    Adams, Sylvia
    Schmid, Peter
    Rugo, Hope S.
    Winer, Eric P.
    Loirat, Delphine
    Awada, Ahmad
    Cescon, David W.
    Iwata, Hiroji
    Campone, Mario
    Nanda, Rita
    Hui, Rina
    Curigliano, Giuseppe
    Toppmeyer, Deborah
    O'Shaughnessy, Joyce
    Loi, Sherene
    Paluch-Shimon, Shani
    Card, Deborah
    Zhao, Jing
    Karantza, Vassiliki
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Trippa, Lorenzo
    Li, Tianyu
    Keenan, Tanya E.
    Winship, Grace
    Andrews, Chelsea
    Osmani, Wafa
    Overmoyer, Beth
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Duda, Dan G.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [9] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Winship, Grace
    Overmoyer, Beth
    Duda, Dan G.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Treatment patterns in metastatic triple-negative breast cancer (mTNBC).
    Jiang, Shan
    Hill, Kala
    Della Varghese
    Waldeck, Adrian Reg
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345